Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures

References

• Giadone RM, Ghosh S, Murphy GJ. Chapter 4 – patient-specific induced pluripotent stem cells for understanding and assessing novel therapeutics for multisystem transthyretin amyloid disease. In: Birbrair A, editor. Novel concepts in iPSC disease modeling. Vol. 15. London: Academic Press; 2022. p. 105–122.
   Google Scholar
• Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol. 2004;16(1):67–75. doi: 10.1097/00002281-200401000-00013
   PubMedGoogle Scholar
• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997;337(13):898–909. doi: 10.1056/NEJM199709253371306
   PubMed Web of Science ®Google Scholar
• Giadone RM, Rosarda JD, Akepati PR, et al. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018;25(3):148–155. doi: 10.1080/13506129.2018.1489228
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1(6):1331–1341. doi: 10.2215/CJN.02740806
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057–1062. doi: 10.1001/archneur.62.7.1057
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19:733–742.
   PubMed Web of Science ®Google Scholar
• Lashuel HA, Wurth C, Woo L, et al. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry. 1999;38(41):13560–13573. doi: 10.1021/bi991021c
   PubMed Web of Science ®Google Scholar
• Giadone RM, Liberti DC, Matte TM, et al. Expression of amyloidogenic transthyretin drives hepatic proteostasis remodeling in an induced pluripotent stem cell model of systemic amyloid disease. Stem Cell Rep. 2020;15(2):515–528. doi: 10.1016/j.stemcr.2020.07.003
   PubMed Web of Science ®Google Scholar
• Grandjean JMD, Plate L, Morimoto RI, et al. Deconvoluting stress-responsive proteostasis signaling pathways for pharmacologic activation using targeted RNA sequencing. ACS Chem Biol. 2019;4:784–795.
   Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi: 10.1093/bioinformatics/btp616
   PubMed Web of Science ®Google Scholar
• Korotkevich G, Sukhov V, Budin N, et al. Fast gene set enrichment analysis. doi: 10.1101/060012. 2016
   Google Scholar
• Buenrostro JD, Giresi PG, Zaba LC, et al. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10(12):1213–1218. doi: 10.1038/nmeth.2688
   PubMed Web of Science ®Google Scholar
• Wei Z, Zhang W, Fang H, et al. esATAC: an easy-to-use systematic pipeline for ATAC-seq data analysis. Bioinformatics. 2018;34(15):2664–2665. doi: 10.1093/bioinformatics/bty141
   PubMed Web of Science ®Google Scholar
• Schubert M, Lindgreen S, Orlando L. AdapterRemoval v2: rapid adapter trimming, identification, and read merging. BMC Res Notes. 2016;9:88.
   PubMedGoogle Scholar
• Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. Nat Methods. 2012;9(4):357–359. doi: 10.1038/nmeth.1923
   PubMed Web of Science ®Google Scholar
• Boyle AP, Guinney J, Crawford GE, et al. F-Seq: a feature density estimator for high-throughput sequence tags. Bioinformatics. 2008;24(21):2537–2538. doi: 10.1093/bioinformatics/btn480
   PubMed Web of Science ®Google Scholar
• Zeller KI, Jegga AG, Aronow BJ, et al. An integrated database of genes responsive to the myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4(10):R69. doi: 10.1186/gb-2003-4-10-r69
   PubMed Web of Science ®Google Scholar
• Grandjean JMD, Madhavan A, Cech L, et al. Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol. 2020;16(10):1052–1061. doi: 10.1038/s41589-020-0584-z
   PubMed Web of Science ®Google Scholar
• Rawat P, Boehning M, Hummel B, et al. Stress-induced nuclear condensation of NELF drives transcriptional downregulation. Mol Cell. 2021;81(5):1013–1026.e11. doi: 10.1016/j.molcel.2021.01.016
   PubMed Web of Science ®Google Scholar
• Gibellini L, Borella R, De Gaetano A, et al. Evidence for mitochondrial Lonp1 expression in the nucleus. Sci Rep. 2022;12(1):10877. doi: 10.1038/s41598-022-14860-0
   PubMed Web of Science ®Google Scholar
• Le Thomas A, Ferri E, Marsters S, et al. Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α. Nat Commun. 2021;12(1):7310. doi: 10.1038/s41467-021-27597-7
   PubMed Web of Science ®Google Scholar
• Dvela-Levitt M, Kost-Alimova M, Emani M, et al. Small molecule targets TMED9 and promotes lysosomal degradation to reverse proteinopathy. Cell. 2019;178(3):521–535.e23. doi: 10.1016/j.cell.2019.07.002
   PubMed Web of Science ®Google Scholar
• Klimtchuk ES, Prokaeva TB, Spencer BH, et al. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis. Amyloid. 2017;24(2):115–122. doi: 10.1080/13506129.2017.1336996
   PubMed Web of Science ®Google Scholar
• Chen JJ, Genereux JC, Qu S, et al. ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein. Chem Biol. 2014;21(11):1564–1574. doi: 10.1016/j.chembiol.2014.09.009
   PubMedGoogle Scholar
• Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A. 2004;101(9):2817–2822. doi: 10.1073/pnas.0400062101
   PubMed Web of Science ®Google Scholar
• Leung A, Nah SK, Reid W, et al. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Rep. 2013;1(5):451–463. doi: 10.1016/j.stemcr.2013.10.003
   PubMed Web of Science ®Google Scholar
• Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide. Circulation. 2012;125(14):1821–1824. doi: 10.1161/CIRCULATIONAHA.111.064246
   PubMed Web of Science ®Google Scholar
• Magalhães J, Eira J, Liz MA. The role of transthyretin in cell biology: impact on human pathophysiology. Cell Mol Life Sci. 2021;78(17–18):6105–6117. doi: 10.1007/s00018-021-03899-3
   PubMed Web of Science ®Google Scholar
• Alemi M, Gaiteiro C, Ribeiro CA, et al. Transthyretin participates in beta-amyloid transport from the brain to the liver – involvement of the low-density lipoprotein receptor-related protein 1? Sci Rep. 2016;6:20164. doi: 10.1038/srep20164
   PubMed Web of Science ®Google Scholar
• Fleming CE, Mar FM, Franquinho F, et al. Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neuritogenic activity. J Neurosci. 2009;29(10):3220–3232. doi: 10.1523/JNEUROSCI.6012-08.2009
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of Aβ toxicity. Proc Natl Acad Sci U S A. 2008;105(7):2681–2686. doi: 10.1073/pnas.0712197105
   PubMed Web of Science ®Google Scholar
• Li X, Masliah E, Reixach N, et al. Neuronal production of transthyretin in human and murine Alzheimer’s disease: is it protective? J Neurosci. 2011;31(35):12483–12490. doi: 10.1523/JNEUROSCI.2417-11.2011
   PubMed Web of Science ®Google Scholar
• Wang X, Cattaneo F, Ryno L, et al. The systemic amyloid precursor transthyretin (TTR) behaves as a neuronal stress protein regulated by HSF1 in SH-SY5Y human neuroblastoma cells and APP23 Alzheimer’s disease model mice. J Neurosci. 2014;34(21):7253–7265. doi: 10.1523/JNEUROSCI.4936-13.2014
   PubMed Web of Science ®Google Scholar
• Chen JJ, Genereux JC, Hyun Suh E, et al. Endoplasmic reticulum proteostasis influences the oligomeric state of an amyloidogenic protein secreted from mammalian cells. Cell Chem Biol. 2016;23(10):1282–1293. doi: 10.1016/j.chembiol.2016.09.001
   PubMed Web of Science ®Google Scholar
• Otaka Y, Nakazato Y, Tsutsui T, et al. Cardiac involvement in heavy and light chain amyloidosis. Medicine. 2019;98(46):e17999. doi: 10.1097/MD.0000000000017999
   PubMed Web of Science ®Google Scholar
• Wang J, Marzolf A, Zhang JCL, et al. Cardiac amyloidosis masked as hypertrophic cardiomyopathy: a case report. Cardiol Res. 2016;7(5):178–180. doi: 10.14740/cr496w
   PubMed Web of Science ®Google Scholar
• Snowden SG, Ebshiana AA, Hye A, et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: a nontargeted metabolomic study. PLoS Med. 2017;14(3):e1002266. doi: 10.1371/journal.pmed.1002266
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang J. Lipid metabolism in Alzheimer’s disease. Neurosci Bull. 2014;30(2):331–345. doi: 10.1007/s12264-013-1410-3
   PubMed Web of Science ®Google Scholar
• Luigetti M, Guglielmino V, Romano A, et al. A metabolic signature of hereditary transthyretin amyloidosis: a pilot study. Int J Mol Sci. 2022;23(24):16133. doi: 10.3390/ijms232416133
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–9634. doi: 10.1073/pnas.1121005109
   PubMed Web of Science ®Google Scholar
• Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1–25. doi: 10.1007/s40120-016-0040-x
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi: 10.1056/NEJMoa1716153
   PubMed Web of Science ®Google Scholar